NL-OMON31757招募中2 期
Bortezomib re-induction therapy combined with donor lymphocyte infusion in patients with relapsed Multiple Myeloma following allogeneic stem cell transplantation - Bortezomib and DLI in relapsed myeloma
niversitair Medisch Centrum Utrecht0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Relapsed multiple myeloma following allogeneic stem cell transplantation
排除标准
- •Active Graft versus Host disease
- •Polyneuropathy > grade 1
- •use of immunosupresssive drugs with the exception of low dose prednisone orally or in ointment
研究者
相似试验
进行中（未招募）
不适用
Bortezomib re-induction therapy combined with donor lymphocyte infusion in patients with relapsed Multiple Myeloma following allogeneic stem cell transplantatiomultiple myeloma patients with relapse or progression of their disease after receiving an allogeneic stem cell transplantationMedDRA version: 8.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2006-005007-34-NLMC20
进行中（未招募）
不适用
Bortezomib in combination with continuous low-dose oral cyclophosphamide and dexamethason followed by maintenance in primary refractory or relapsed bortezomib naïve multiple myeloma patientsEUCTR2008-004822-17-NLniversity Medical Center
已完成
2 期
Bortezomib in combination with continuous low-dose oral cyclophosphamide and dexamethason followed by maintenance in primary refractory or relapsed bortezomib naïve multiple myeloma patientsM. Kahler.10018849Multiple myelomaNL-OMON38293niversitair Medisch Centrum Groningen73
已完成
不适用
Bortezomib (Velcade®) therapy combined with Donor Lymphocyte Infusion in patients with relapsed multiple myeloma following allogeneic stem cell transplantatioMultiple myelomaCancerISRCTN53810679niversity Medical Centre Utrecht (UMCU) (The Netherlands)20
进行中（未招募）
1 期
Induction therapy with bortezomib-melphalan and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide and dexamethasone plus/minus daratumumab, 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: trial for elderly fit newly diagnosed multiple myeloma patients aged between 65 and 80 yearsMultiple myelomaEUCTR2017-000044-18-ESFundación PETHEMA462